Apligraf, a manufactured living human skin equivalent, was the first true c
omposite tissue analog to become commercially available. It has been approv
ed by the FDA for the treatment of venous leg ulcers and diabetic foot ulce
rs. The tissue engineered bi-layered skin equivalent has both an epidermis
and a dermis, which consist of keratinocytes and fibroblasts derived from n
eonatal foreskin and bovine collagen. The skin equivalent produces a great
number of cytokines and growth factors and is immunologically well tolerate
d. The product is easy to handle in clinical use and can be applied in an o
utpatient setting.